Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lipopolysaccharide-containing Gram-negative outer membrane is a highly asymmetric lipid bilayer that serves as the primary permeability barrier protecting Gram-negative bacteria from toxic environmental agents, including many classes of antibiotics. The outer leaflet of this membrane is composed almost entirely of lipopolysaccharide (LPS), a complex glycolipid whose lipid A component anchors the molecule and acts as a potent endotoxin. This unique structure restricts the passive diffusion of hydrophobic and large hydrophilic molecules, contributing significantly to the intrinsic multidrug resistance of Gram-negative pathogens. Therapeutic agents such as polymyxins target this membrane by electrostatically interacting with the negatively charged phosphate groups of LPS, displacing divalent cations, and physically disrupting membrane integrity to cause cell death. However, targeting this structure is associated with notable clinical challenges, including severe nephrotoxicity and neurotoxicity, as well as the potential for rapid endotoxin release leading to systemic inflammatory responses.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide-containing Gram-negative outer membrane (LPS-containing GNOM).